Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04030039
Other study ID # DTXY017
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date May 1, 2017
Est. completion date December 30, 2020

Study information

Verified date July 2019
Source Beijing Ditan Hospital
Contact Yao Xie, Doctor
Phone 010-84322284
Email xieyao00120184@sina.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

All chronic hepatitis B (CHB) patients were diagnosed and treated in the liver disease department of the Hepatology Center of Beijing Ditan Hospital affiliated to Capital Medical University and those who received antiviral therapy (interferon and nucleoside analogues) reached HBsAg<100 IU/ml. The enrolled subjects were divided into the following six observation cohorts: 1) CHB patients in the immunological control period, without any clinical treatment intervention; 2) After interferon therapy, HBsAg<100 IU/ml, continued interferon therapy; 3) After interferon therapy, HBsAg<100 IU/ml, stopped interferon treatment; 4) After interferon therapy, HBsAg<100 IU/ml, sequential nucleoside analog treatment; 5) After nucleoside analogue treatment, HBsAg<100 IU/ml, sequential interferon treatment; 6) After treated with nucleoside analogues, HBsAg<100 IU/ml, continuing the nucleoside analog treatment. The follow-up observation period was 96 weeks under non-planned intervention. During the observation period, HBV indicators and biochemical indicators, serum AFP and liver imaging (liver ultrasound) were examined regularly. The main evaluation index was the incidence of HBsAg disappearance during the observation period. Secondary evaluation indicators: the rate of HBV DNA turning positive, the rate of HBeAg turning positive and hepatitis incidence. To observe the inactive carrier status of low HBsAg content and the incidence of HBsAg disappearance, clinical outcomes and influencing factors in patients with CHB under different antiviral interventions.


Description:

This study is a clinical observational cohort study. All chronic hepatitis B patients were diagnosed and treated in the liver disease department of the Hepatology Center of Beijing Ditan Hospital affiliated to Capital Medical University and those who received antiviral therapy (interferon and nucleoside analogues) reached HBsAg<100 IU/ml. The enrolled subjects were divided into the following six observation cohorts: 1) chronic Hepatitis B patients in the immunological control period, without any clinical treatment intervention in this cohort; 2) After interferon therapy, HBsAg<100 IU/ml, continued interferon therapy in this cohort; 3) After interferon therapy, HBsAg<100 IU/ml, stopped interferon treatment in this cohort; 4) After interferon therapy, HBsAg<100 IU/ml, sequential nucleoside analog treatment in this cohort; 5) After nucleoside analogue treatment, HBsAg<100 IU/ml, sequential interferon treatment in this cohort; 6) After treated with nucleoside analogues, HBsAg<100 IU/ml, continuing the nucleoside analog treatment in this cohort. The follow-up observation period was 96 weeks under non-planned intervention. During the observation period, HBV DNA loads, HBsAg/anti-HBs, HBeAg/anti-HBe and biochemical indicators, serum AFP and liver imaging (liver ultrasound) were examined regularly. The main evaluation index was the incidence of HBsAg disappearance during the observation period. Secondary evaluation indicators: the rate of HBV DNA turning positive, the rate of HBeAg turning positive and hepatitis incidence. To observe the inactive carrier status of low HBsAg content and the incidence of HBsAg disappearance, clinical outcomes and influencing factors in patients with CHB under different antiviral interventions.


Recruitment information / eligibility

Status Recruiting
Enrollment 420
Est. completion date December 30, 2020
Est. primary completion date December 30, 2020
Accepts healthy volunteers No
Gender All
Age group 20 Years to 70 Years
Eligibility Inclusion Criteria:

- Inactive carrier status and chronic hepatitis B (CHB) patients with anti-viral therapy (interferon and nucleoside analogues) reaching HBsAg < 100 IU/ml.

Exclusion Criteria:

- coinfection with other viruses including HCV, HDV, and HIV;

- syphilis antibody positive;

- co-exist other liver diseases including alcoholic liver disease, metabolic liver disease, fatty liver, drug induce liver injury, and autoimmune liver disease;

- complication of cirrhosis or liver cancer.

Study Design


Intervention

Drug:
Interferon
chronic hepatitis B patients with interferon therapy
nucleoside analogues
chronic hepatitis B patients with interferon therapy

Locations

Country Name City State
China liver disease center, Beijing Ditan Hospital Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Beijing Ditan Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other liver cancer during the 96-week study period in different observation cohorts Incidence liver cancer during the 96-week study period in different observation cohorts Incidence 96 weeks
Other Hepatitis episodes during the 96-week study period in different observation cohorts Incidence Hepatitis episodes during the 96-week study period in different observation cohorts Incidence 96 weeks
Other cirrhosis decompensation during the 96-week study period in different observation cohorts Incidence cirrhosis decompensation during the 96-week study period in different observation cohorts Incidence 96 weeks
Other its complications during the 96-week study period in different observation cohorts Incidence its complications during the 96-week study period in different observation cohorts Incidence 96 weeks
Primary The incidence of HBsAg disappearance during the 96-week study in different observation cohorts The incidence of HBsAg disappearance during the 96-week study in different observation cohorts 96 weeks
Secondary HBV DNA re-yang rate during the 96-week study period in different observation cohorts HBV DNA re-yang rate and HBeAg re-yang rate during the 96-week study period in different observation cohorts 96 weeks
Secondary HBeAg re-yang rate during the 96-week study HBeAg re-yang rate during the 96-week study 96 weeks
See also
  Status Clinical Trial Phase
Completed NCT03329820 - Quality of Life and Health Utility of Patients With CHB Infections N/A
Recruiting NCT03210506 - The Changes of Cytokines During Antiviral Therapy N/A
Recruiting NCT03208998 - The Changes of Natural Killer Cells Frequency and Function During Antiviral Therapy Phase 4
Recruiting NCT03209011 - The Changes of CD4+T Cells Frequency and Function During Antiviral Therapy Phase 4
Recruiting NCT03209037 - The Changes of CD8+T Cells Frequency and Function During Antiviral Therapy Phase 4
Recruiting NCT03210493 - The Changes of Treg Cells Frequency and Function During Antiviral Therapy N/A
Recruiting NCT03210467 - The Changes of Plasmacytoid Dendritic Cells Frequency and Function During Antiviral Therapy N/A
Recruiting NCT04638439 - The Safety and Efficacy of Sequential Treatment of Ropeginterferon Alfa-2b (P1101) and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D Infection Phase 1
Recruiting NCT03587467 - Study on Gut Microbiota in Chronic HBV Infected Patients
Completed NCT05355467 - Efficacy and Safety of Ricovir® in Maintaining Durability of Viral Response in Chronic Hepatitis B Patients Who Have Been Treated With Viread® and Have Undetectable HBV DNA in Serum Phase 4
Recruiting NCT04135235 - Effect and Safety of Propofol Fumarate for Mother-to-child Blocking of Hepatitis B